Healthy Skepticism Library item: 11797
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: Journal Article
Lofstedt RE.
The impact of the cox-2 inhibitor issue on perceptions of the pharmaceutical industry: content analysis and communication implications.
J Health Commun 2007 Jul-Aug; 12:(5):471-91
http://www.informaworld.com/smpp/content?content=10.1080/10810730701438724
Abstract:
The field of risk communication has its roots in the environmental, chemical, space, and nuclear arenas. As a number of these sectors have now vastly improved their communication strategies, attention is being placed on sectors that have been more problematic as of late. Examples of such sectors, include the food industries and the pharmaceutical/health sector. This article focuses on how large, multinational pharmaceutical companies can better communicate risks by analysis of one specific case, namely, that of the Cox-2 controversy.(1) For purposes of this article, risk communication is best described as “the flow of information and risk evaluations back and forth between academic experts, regulatory practitioners, interest groups and the general public,” and “big pharma” refers to the more traditional R & D-based, innovative pharmaceutical companies.
Keywords:
Publication Types:
Research Support, Non-U.S. Gov't
MeSH Terms:
Advertising*
Communication*
Cyclooxygenase 2 Inhibitors/adverse effects*
Drug Industry*
Drug Toxicity*
Government Regulation
Health Policy
Humans
Perception*
Pilot Projects
Public Relations*
Risk
United States
United States Food and Drug Administration
Substances:
Cyclooxygenase 2 Inhibitors
